Neogenomics Stock Analysis
| NEO Stock | USD 11.50 0.15 1.32% |
IPO Date 2nd of November 1999 | 200 Day MA 9.0707 | 50 Day MA 12.2262 | Beta 1.582 |
NeoGenomics holds a debt-to-equity ratio of 0.586. At this time, NeoGenomics' Debt To Equity is very stable compared to the past year. As of the 11th of February 2026, Interest Debt Per Share is likely to grow to 22.83, though Net Debt To EBITDA is likely to grow to (172.31). With a high degree of financial leverage come high-interest payments, which usually reduce NeoGenomics' Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
NeoGenomics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. NeoGenomics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps NeoGenomics Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect NeoGenomics' stakeholders.
For many companies, including NeoGenomics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for NeoGenomics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, NeoGenomics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 1.7518 | Enterprise Value Ebitda (27.92) | Price Sales 2.0982 | Shares Float 112.9 M | Wall Street Target Price 14.4286 |
NeoGenomics is undervalued with Real Value of 12.96 and Target Price of 14.43. The main objective of NeoGenomics stock analysis is to determine its intrinsic value, which is an estimate of what NeoGenomics is worth, separate from its market price. There are two main types of NeoGenomics' stock analysis: fundamental analysis and technical analysis.
The NeoGenomics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. NeoGenomics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. NeoGenomics Stock trading window is adjusted to America/New York timezone.
NeoGenomics | Build AI portfolio with NeoGenomics Stock |
NeoGenomics Stock Analysis Notes
About 99.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.75. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. NeoGenomics has Price/Earnings (P/E) ratio of 272.37. The entity recorded a loss per share of 0.9. The firm had not issued any dividends in recent years. NeoGenomics had 1:100 split on the 16th of April 2003. NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company was founded in 2001 and is headquartered in Fort Myers, Florida. Neogenomics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 2000 people. To find out more about NeoGenomics contact Christopher BSc at 239 768 0600 or learn more at https://www.neogenomics.com.NeoGenomics Investment Alerts
| The company reported the last year's revenue of 660.57 M. Reported Net Loss for the year was (78.73 M) with profit before taxes, overhead, and interest of 307.81 M. | |
| NeoGenomics has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Neo Financial secures 68.5M in equity, backed by 100 Canadian investors to fuel securitization strategy |
NeoGenomics Largest EPS Surprises
Earnings surprises can significantly impact NeoGenomics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2011-10-19 | 2011-09-30 | -0.01 | -0.0033 | 0.0067 | 67 | ||
2015-07-23 | 2015-06-30 | -0.01 | -0.0029 | 0.0071 | 71 | ||
2013-02-14 | 2012-12-31 | -0.01 | -0.0023 | 0.0077 | 77 |
NeoGenomics Environmental, Social, and Governance (ESG) Scores
NeoGenomics' ESG score is a quantitative measure that evaluates NeoGenomics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of NeoGenomics' operations that may have significant financial implications and affect NeoGenomics' stock price as well as guide investors towards more socially responsible investments.
NeoGenomics Stock Institutional Investors
| Shares | Geode Capital Management, Llc | 2025-06-30 | 3.2 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 2.5 M | Gw&k Investment Management, Llc | 2025-06-30 | 2.5 M | Segall Bryant & Hamill | 2025-06-30 | 2.4 M | Deerfield Management Co | 2025-06-30 | 2.1 M | Hhg Plc | 2025-06-30 | 2 M | Jennison Associates Llc | 2025-06-30 | 1.7 M | Bank Of America Corp | 2025-06-30 | 1.5 M | Goldman Sachs Group Inc | 2025-06-30 | 1.5 M | Blackrock Inc | 2025-06-30 | 19.4 M | Vanguard Group Inc | 2025-06-30 | 14.1 M |
NeoGenomics Market Capitalization
The company currently falls under 'Mid-Cap' category with a total capitalization of 1.49 B.NeoGenomics Profitablity
The company has Net Profit Margin of (0.16) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.08) %, which entails that for every $100 of revenue, it lost $0.08.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.09) | (0.10) | |
| Return On Capital Employed | (0.08) | (0.08) | |
| Return On Assets | (0.04) | (0.05) | |
| Return On Equity | (0.10) | (0.10) |
Management Efficiency
NeoGenomics has Return on Asset of (0.0303) % which means that on every $100 spent on assets, it lost $0.0303. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.1299) %, meaning that it generated no profit with money invested by stockholders. NeoGenomics' management efficiency ratios could be used to measure how well NeoGenomics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 11th of February 2026, Return On Tangible Assets is likely to drop to -0.1. In addition to that, Return On Capital Employed is likely to grow to -0.08. At this time, NeoGenomics' Fixed Asset Turnover is very stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 32.06 | 33.66 | |
| Tangible Book Value Per Share | 1.42 | 1.37 | |
| Enterprise Value Over EBITDA | (499.11) | (474.15) | |
| Price Book Value Ratio | 0.53 | 0.51 | |
| Enterprise Value Multiple | (499.11) | (474.15) | |
| Price Fair Value | 0.53 | 0.51 |
NeoGenomics benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Technical Drivers
As of the 11th of February 2026, NeoGenomics secures the Downside Deviation of 2.48, risk adjusted performance of 0.0631, and Mean Deviation of 1.85. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NeoGenomics, as well as the relationship between them.NeoGenomics Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in NeoGenomics price series with the more recent values given greater weights.
NeoGenomics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NeoGenomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on NeoGenomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NeoGenomics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
NeoGenomics Outstanding Bonds
NeoGenomics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. NeoGenomics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most NeoGenomics bonds can be classified according to their maturity, which is the date when NeoGenomics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| TNEMAK 3625 28 JUN 31 Corp BondUS64045DAC83 | View | |
| US64049MAB63 Corp BondUS64049MAB63 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
NeoGenomics Predictive Daily Indicators
NeoGenomics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of NeoGenomics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 63535.83 | |||
| Daily Balance Of Power | 0.3261 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 11.56 | |||
| Day Typical Price | 11.54 | |||
| Price Action Indicator | 0.015 | |||
| Period Momentum Indicator | 0.15 |
NeoGenomics Corporate Filings
F4 | 21st of January 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 15th of January 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 12th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 5th of January 2026 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 30th of December 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 9th of December 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 3rd of December 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 2nd of December 2025 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
NeoGenomics Forecast Models
NeoGenomics' time-series forecasting models are one of many NeoGenomics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary NeoGenomics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.NeoGenomics Bond Ratings
NeoGenomics financial ratings play a critical role in determining how much NeoGenomics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for NeoGenomics' borrowing costs.| Piotroski F Score | 4 | Poor | View |
| Beneish M Score | (2.82) | Unlikely Manipulator | View |
NeoGenomics Debt to Cash Allocation
As NeoGenomics follows its natural business cycle, the capital allocation decisions will not magically go away. NeoGenomics' decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
NeoGenomics has 605.33 M in debt with debt to equity (D/E) ratio of 0.59, which is OK given its current industry classification. NeoGenomics has a current ratio of 7.38, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. That said, strategic use of leverage may enable NeoGenomics to fund expansion initiatives and generate superior returns. NeoGenomics Total Assets Over Time
NeoGenomics Assets Financed by Debt
The debt-to-assets ratio shows the degree to which NeoGenomics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.NeoGenomics Debt Ratio | 36.0 |
NeoGenomics Corporate Bonds Issued
NeoGenomics Net Debt
Net Debt |
|
About NeoGenomics Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how NeoGenomics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling NeoGenomics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as NeoGenomics. By using and applying NeoGenomics Stock analysis, traders can create a robust methodology for identifying NeoGenomics entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.11) | (0.12) | |
| Operating Profit Margin | (0.14) | (0.13) | |
| Net Loss | (0.12) | (0.11) | |
| Gross Profit Margin | 0.40 | 0.26 |
Current NeoGenomics Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. NeoGenomics analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. NeoGenomics analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 14.43 | Buy | 14 | Odds |
Most NeoGenomics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand NeoGenomics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of NeoGenomics, talking to its executives and customers, or listening to NeoGenomics conference calls.
NeoGenomics Stock Analysis Indicators
NeoGenomics stock analysis indicators help investors evaluate how NeoGenomics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading NeoGenomics shares will generate the highest return on investment. By understating and applying NeoGenomics stock analysis, traders can identify NeoGenomics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 342.5 M | |
| Total Stockholder Equity | 902.3 M | |
| Capital Lease Obligations | 64.2 M | |
| Property Plant And Equipment Net | 173.7 M | |
| Cash And Short Term Investments | 386.8 M | |
| Cash | 367 M | |
| 50 Day M A | 12.2262 | |
| Net Interest Income | 11.8 M | |
| Total Current Liabilities | 301.2 M | |
| Forward Price Earnings | 222.2222 | |
| Interest Expense | 6.6 M | |
| Stock Based Compensation | 33.4 M | |
| Long Term Debt | 340.3 M | |
| Common Stock Shares Outstanding | 25.3 M | |
| Total Cashflows From Investing Activities | 12.9 M | |
| Tax Provision | -1.9 M | |
| Quarterly Earnings Growth Y O Y | 1.306 | |
| Accounts Payable | 21.6 M | |
| Net Debt | 238.3 M | |
| Other Operating Expenses | 752.7 M | |
| Non Current Assets Total | 1 B | |
| Liabilities And Stockholders Equity | 1.6 B | |
| Non Currrent Assets Other | 5.9 M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in discontinued. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Will Health Care Providers & Services sector continue expanding? Could NeoGenomics diversify its offerings? Factors like these will boost the valuation of NeoGenomics. Anticipated expansion of NeoGenomics directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every NeoGenomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.306 | Earnings Share (0.90) | Revenue Per Share | Quarterly Revenue Growth 0.119 | Return On Assets |
Investors evaluate NeoGenomics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating NeoGenomics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause NeoGenomics' market price to deviate significantly from intrinsic value.
It's important to distinguish between NeoGenomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NeoGenomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, NeoGenomics' market price signifies the transaction level at which participants voluntarily complete trades.